Developing a method for the quantitative determination of the P-glycoprotein activity marker fexofenadine in blood plasma

Author： Ramenskaya G.   Skuridina E.   Krasnykh L.  

Publisher： Springer Publishing Company

ISSN： 0091-150X

Source： Pharmaceutical Chemistry Journal, Vol.40, Iss.12, 2006-12, pp. : 686-689

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells

By Storch Caroline   Klimm Hans-Dieter   Heinrich Tilman   Haefeli Walter   Weiss Johanna  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 376, Iss. 1-2, 2007-10 ,pp. : 135-143

Springer Publishing Company

Access to resources Recommend Favorite

Influence of ABCB1 Gene Polymorphisms and P-Glycoprotein Activity on Cyclosporine Pharmacokinetics in Peripheral Blood Mononuclear Cells in Healthy Volunteers

By  

Drug Metabolism Letters, Vol. 2, Iss. 2, 2008-04 ,pp. : 76-82

Bentham Science Publishers

Access to resources Recommend Favorite

Structure-activity relationship of P-glycoprotein substrates and modifiers

By Seelig A.   Landwojtowicz E.  

European Journal of Pharmaceutical Sciences, Vol. 12, Iss. 1, 2000-11 ,pp. : 31-40

Elsevier

Access to resources Recommend Favorite

Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease

By  

Current Pharmaceutical Design, Vol. 17, Iss. 26, 2011-09 ,pp. : 2771-2777

Bentham Science Publishers

Access to resources Recommend Favorite

A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain

By Roberts Derek J   Goralski Kerry B  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 10, 2008-10 ,pp. : 1245-1264

Informa Healthcare

Access to resources Recommend Favorite